MD Anderson, Oncora Medical cooperate on precision radiation oncology

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Oncora Medical, a precision radiation oncology software company, and MD Anderson Cancer Center announced a strategic alliance focusing on building the next generation of precision medicine software for radiation oncology.

During phase I, MD Anderson oncologists and information technology professionals will work with Oncora’s team of data scientists and engineers to install Oncora’s Precision Radiation Oncology Platform, a software system built to assist radiation oncologists in the development of personalized treatment plans based on outcome predictions.

Oncora’s platform will be fueled by data from MD Anderson’s electronic medical record system, tumor registry, radiation therapy planning system, and Brocade, an innovative software product developed by MD Anderson in 2014. Brocade was developed by Benjamin Smith, associate professor of radiation oncology, and author of a study published in the April 2016 issue of the Journal of the American College of Radiology that demonstrated a 70 percent reduction in the time physicians spend documenting clinical data using Brocade.

Brocade, a web-based clinical documentation tool used by MD Anderson radiation oncologists, enables intuitive collection of structured data about patient diagnosis, treatment and radiation side effects, and generates narrative-style clinical documentation for medical records. Oncora will engineer complete interoperability between their Precision Radiation Oncology Platform and Brocade to explore the potential value of a combined product.

YOU MAY BE INTERESTED IN

Shearwood McClelland III’s grandfather was a ditchdigger who dreamed that his six Black daughters would become doctors. McClelland’s mother did not disappoint—she became the first Black woman board-certified in maternal fetal medicine in the history of the United States.  Now, McClelland is the chief medical officer of Cancer Health Equity at the University of Oklahoma...

As oncology enters a new era of precision medicine, the Food and Drug Administration’s evolving biomarker strategy aims to ensure that life-saving therapies are tailored to individual patient needs, fostering safer and more effective treatments.  Historically, therapies were approved with broad indications based on overall efficacy, even when outcomes for biomarker-positive and -negative patients were...

In the evolving landscape of pediatric oncology, survivorship research has become an essential component of our mission to improve long-term patient outcomes. At City of Hope, we are focused on not only curing childhood cancers but also ensuring that survivors live the healthiest lives possible. A significant part of my research has been dedicated to mitigating the long-term toxicities of cancer therapy—particularly cardiovascular complications that can arise decades after treatment.

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login